Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
ketamine, phencyclidine, methoxetamine +2 moreketamine, phencyclidine, methoxetamine, methoxphenidine, dextromethorphan show less
Diphenidine
Diphenidine is a synthetic dissociative of the diarylethylamine class. It is closely related to phencyclidine and ketamine, but binds their shared target with greater potency. It blocks glutamate signaling in the brain,[1] cutting off normal nerve communication and producing a state of deep disconnection.
Diphenidine is a synthetic dissociative of the diarylethylamine class. It shares a synthetic lineage with phencyclidine and ketamine, distinguished by higher receptor potency and a more amnestic character. Diphenidine is an NMDA receptor antagonist, producing its effects by blocking glutamate-driven calcium signaling in the brain.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
ketamine, phencyclidine, methoxetamine +2 moreketamine, phencyclidine, methoxetamine, methoxphenidine, dextromethorphan show less
First synthesized in 1924,[2] diphenidine was ignored by pharmacologists for nearly nine decades. It resurfaced in 2013 as a research chemical sold online as a legal substitute for ketamine,[3][4] spreading rapidly before hospitalizations and fatalities prompted international action. The United Nations placed it on Schedule II in April 2021.[5]
Subjective effects include deep disconnection from surroundings, hallucinations, depersonalization, euphoria, and profound memory loss. The experience is heavier and more enveloping than ketamine — a dense dissociative fog in which memories of what happened frequently fail to form.[6] Severe agitation, confusion, and paranoia are characteristic unwanted effects.[7][5]
Diphenidine triggers dopamine release in the brain's reward circuits,[8] signaling abuse liability; no human dependence cases have been published.[9] The dominant acute risks are cardiovascular stress and severe agitation; 48 deaths are on record worldwide, most involving multiple substances.[9] No controlled human studies have been conducted; the evidence rests on case reports, animal data, and one comprehensive binding study.[1]
History[edit]
Discovery
Diphenidine was first synthesized in 1924 by Christiaen using a Bruylants reaction[2] — the same chemistry that later yielded phencyclidine. It sat unexamined for roughly 65 years. Related structures were patented as NMDA antagonists for neuroprotection in 1989,[10] but diphenidine itself was never developed clinically.
Research chemical emergence
Diphenidine appeared on UK internet markets in 2013, sold as a legal alternative to ketamine as regulators moved against methoxetamine.[3][4] It was detected in Japan[11] and on Canadian vendor sites[12] in 2014. The first scientific characterization was published in 2015,[13] with comprehensive binding data across 46 receptor sites following in 2016.[1]
Scheduling
Hospitalizations and deaths accumulated rapidly.[7][14] Canada scheduled diphenidine in 2016[12] and the UK banned all novel psychoactive substances the same year.[15] The UN placed it on Schedule II in April 2021,[5] and the UK Advisory Council recommended Class B control in May 2023.[9]
The name diphenidine derives from its two phenyl groups and piperidine ring. It belongs to a structural family alongside pharmaceutical agents — lefetamine, lanicemine, and remacemide — none of which achieved clinical use.[1][4] A 2025 crystallography paper incorrectly dates diphenidine to 2013, reflecting how completely its 1924 synthesis was forgotten.[16]
Chemistry[edit]
Structural class
Diphenidine belongs to the 1,2-diarylethylamine class — two aromatic rings connected through a short carbon bridge.[1][4] This scaffold shares a synthetic lineage with phencyclidine and ketamine through the Bruylants reaction.[2] Its molecular formula is C₁₉H₂₃N (molecular weight 265.4 g/mol).
Molecular structure
| Molecular formula | C₁₉H₂₃N |
| Molecular weight | 265.4 g/mol |
Pharmacology[edit]
Mechanism of action
Diphenidine blocks glutamate signaling by entering open ion channels in the brain and stopping calcium flow.[1][13] This is the same mechanism as phencyclidine and ketamine, producing the same category of dissociative effects. Diphenidine binds this target with substantially greater affinity than ketamine.[1]
It also weakly slows dopamine recycling and, unlike structurally related compounds, increases dopamine release in the brain's reward hub.[8] Methoxphenidine does not share this property.[8] This distinction suggests diphenidine carries greater reinforcement potential than its close structural analog.
Pharmacokinetics
No controlled human pharmacokinetic studies have been conducted. The liver breaks diphenidine down through several pathways involving multiple enzymes.[3] The only human blood concentration on record comes from a single non-fatal poisoning in Italy: 308 ng/mL in plasma and 631 ng/mL in urine.[6]
Neuroscience[edit]
Where it acts
No direct brain imaging studies have been conducted with diphenidine. Based on ketamine research, blocking glutamate signaling disrupts communication between brain regions — raising cortical excitability while reducing normal sensory filtering.[7] The result is sensory input cut off from normal processing: the neurological core of the dissociative state. Dopamine release in reward circuits[8] may drive the euphoria some experience.[6]
Why it matters
When glutamate signaling is blocked, inhibitory brain cells stop functioning normally, and excitatory activity escalates. This generates hallucinations, paranoid thinking, and disorganized perception.[1][5] Diphenidine's clinical presentations fit this pattern closely.
Whether diphenidine's two molecular forms differ in brain effects has never been tested.[17] Its dopamine-releasing properties suggest abuse liability,[8] but no human dependence cases have confirmed or denied this.[9]
Subjective Effects[edit]
Diphenidine pulls awareness into a dense, enveloping dissociative fog. Thought, sensation, and memory lose their normal coherence.[6] It is defined less by what it adds to experience and more by what it removes.
Compared to ketamine, diphenidine occupies similar territory but with a heavier, more amnestic character.[7][1] Ketamine allows a degree of conscious observation from within the dissociated state. Diphenidine tends to swallow that perspective entirely.
First synthesized in 1924 via a Bruylants reaction,[2] diphenidine remained pharmacologically unexplored for nearly nine decades. It emerged on internet research chemical markets in 2013 as a legal alternative to ketamine and PCP,[3][4] prompting the first scientific characterization two years later.[5] Diphenidine was placed on Schedule II of the Convention on Psychotropic Substances in April 2021 following a WHO recommendation.[6]
Subjective effects include dissociation, hallucinations, depersonalization, amnesia, and euphoria. The experience is heavy and enveloping — a dense dissociative fog in which memory formation largely ceases, distinguishing it from the lighter, more lucid detachment of ketamine.[7] Severe agitation, confusion, and paranoia are characteristic unsought effects.[8][6]
No human dependence cases have been published, but diphenidine increases dopamine release in reward circuits — a mechanistic signal for addictive potential absent in related compounds.[9][10] Acute toxicity centers on cardiovascular stress and severe agitation; 48 deaths have been identified worldwide, most involving other substances.[10] No controlled human studies have been conducted; the current understanding rests on case reports, animal data, and a single comprehensive binding study.[1]
History[edit]
Discovery
Diphenidine was first synthesized in 1924 by Christiaen via a Bruylants reaction — the same chemistry that would later yield phencyclidine in 1956.[2] The compound sat unexamined in the chemical literature for roughly 65 years with no pharmacological investigation. Pharmaceutical interest in the diarylethylamine scaffold emerged in 1989 when Gray and Cheng patented related structures as NMDA antagonists for neuroprotection,[11] but diphenidine itself was never developed clinically.
Research chemical emergence
Diphenidine appeared on UK internet markets in 2013, marketed as a legal alternative to ketamine and PCP amid regulatory pressure on methoxetamine.[3][4] It was detected in Japanese herbal products in 2014[12] and on Canadian vendor sites the same year.[13] The first scientific characterization was published in 2015,[5] with comprehensive binding data across 46 receptor sites following in 2016.[1]
Scheduling
Case reports of hospitalizations and fatalities accumulated rapidly.[8][14] Canada scheduled diphenidine in 2016[13] and the UK imposed a blanket ban under the Psychoactive Substances Act the same year.[15] The WHO Expert Committee recommended international scheduling in October 2020; the Commission on Narcotic Drugs adopted the recommendation in April 2021, placing diphenidine on Schedule II of the Convention on Psychotropic Substances.[6] The UK Advisory Council on the Misuse of Drugs subsequently recommended Class B control in May 2023.[10]
The name diphenidine derives from its two phenyl groups and piperidine ring. The compound belongs to a structural family that includes pharmaceutical agents — lefetamine, lanicemine, and remacemide — though none achieved widespread clinical use.[1][4]
Chemistry[edit]
Structural class
Diphenidine belongs to the 1,2-diarylethylamine class, defined by two aromatic rings connected through a two-carbon ethylamine bridge. This scaffold is shared with several pharmaceutical compounds including lefetamine, lanicemine, and remacemide.[1][4] The class shares a synthetic lineage with arylcyclohexylamines such as phencyclidine and ketamine through the Bruylants reaction.[2]
Molecular structure
The molecule consists of a piperidine ring bonded to a 1,2-diphenylethyl chain. The IUPAC name is 1-(1,2-diphenylethyl)piperidine.
| Molecular formula | C₁₉H₂₃N |
| Molecular weight | 265.4 g/mol |
Both phenyl groups are unsubstituted. Methoxy substitution at the para position of one ring yields methoxphenidine (2-MeO-diphenidine), while fluorination of the aromatic rings produces a family of derivatives studied crystallographically.[16]
Stereochemistry
Diphenidine contains one chirality centre, giving rise to R and S enantiomers. Market samples are sold as a racemic mixture.[17] Whether the enantiomers differ in potency or receptor selectivity is unknown — no enantioselective pharmacological testing has been published.
Pharmacology[edit]
Mechanism of action
Diphenidine is an uncompetitive NMDA receptor antagonist — it enters the ion channel when the receptor is open and blocks calcium flow, preventing normal glutamate signaling.[1][5] This is the same mechanism by which phencyclidine and ketamine produce dissociative effects. Diphenidine binds the NMDA channel with substantially greater affinity than ketamine.[1]
Beyond NMDA blockade, diphenidine weakly inhibits dopamine reuptake.[1] This dopaminergic component has functional consequences: diphenidine increases dopamine release in the nucleus accumbens (the brain's primary reward hub), whereas the structurally related methoxphenidine does not.[9] This distinction suggests diphenidine may carry greater reinforcement potential than its methoxy structural analog.
Diphenidine shows negligible activity at the SERT[1] and moderate affinity for sigma receptors, though precise values for the latter are difficult to extract from published data.[1]
Pharmacokinetics
No controlled human pharmacokinetic studies exist for diphenidine. Key parameters — half-life, oral bioavailability, and volume of distribution — are entirely uncharacterized in humans.
Metabolic pathways have been mapped using rat urine and human liver preparations.[3] The liver breaks diphenidine down through hydroxylation of both the aromatic rings and the piperidine ring, followed by conjugation reactions. Multiple liver enzymes participate in this process.[3]
The only published human blood concentration comes from a single non-fatal poisoning case in Italy: plasma 308 ng/mL and urine 631 ng/mL at hospital presentation.[7] These are snapshot values from a single time point, not pharmacokinetic curves.
Neuroscience[edit]
Where it acts
No direct neuroimaging or electrophysiology studies have been conducted with diphenidine in humans. Based on class-level evidence from ketamine research, diphenidine's NMDA blockade disrupts communication between cortical and subcortical brain regions — increasing cortical excitability through disinhibition of inhibitory interneurons while reducing thalamic gating of sensory input.[8] The result is sensory disconnection from higher-order processing: the neurological basis of the dissociative state.
Simultaneously, dopamine release in the nucleus accumbens[9] activates the brain's reward circuitry, which may account for the euphoria some users report[7] and represents a mechanistic basis for reinforcement potential.
Why it matters
The NMDA hypofunction model — the leading framework for understanding how NMDA antagonists produce psychosis-like states — predicts that blocking NMDA receptors on inhibitory neurons unleashes excitatory activity, generating hallucinations, delusions, and thought disorganization. Diphenidine's clinical presentation — hallucinations, paranoia, disrupted sensory gating[1][6] — fits this model closely.
Whether diphenidine also triggers neuroplastic changes (as ketamine does through downstream glutamate and growth factor signaling) is unknown.
Several fundamental questions remain unanswered. Whether diphenidine's enantiomers differ in neural effects — as ketamine's do — has never been tested, since the compound is used only as a racemic mixture.[17] Whether chronic use causes the neurotoxic brain lesions associated with high-dose NMDA antagonists in animal studies has not been investigated.
Subjective Effects[edit]
Diphenidine produces a heavy, enveloping dissociative state dominated by memory disruption. At lower doses, the experience manifests as detachment and mild perceptual distortion; at higher doses, it deepens into full dissociation with prominent anterograde amnesia — users frequently cannot recall the experience in detail afterward.[7] Set and setting strongly influence whether the state is experienced as euphoric or distressing, and smoked administration produces a more abrupt, disorienting entry than the gradual oral onset.
Compared to ketamine, diphenidine occupies a similar functional space but with a subjectively heavier, more amnestic character and a more pronounced cardiovascular burden.[8][1]
Effect Grid
At common doses (75–120 mg oral), the full dissociative experience manifests. Pronounced detachment from body and environment occurs alongside perceptual distortions — spatial warping, altered sound processing, and visual field changes. Hallucinations may emerge, ranging from abstract patterning to more complex scenes. Depersonalization and derealization become prominent. Anterograde amnesia for portions of the experience is common.
Cardiovascular effects are significant at this range: hypertension and tachycardia were documented in 76% and 47% of hospitalized cases, respectively. Physical coordination is substantially impaired; walking becomes difficult or impossible.
The experience demands 3–5 hours of committed time with no obligations. Sleep is typically difficult until effects fully resolve.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Proprioceptive distortion · Vestibular distortion · Visual haze / noise · Ganzfeld effect · Auditory distortion · Peripheral vision distortion · Tracers · Visual drifting · Music enhancement · Auditory suppression · Auditory misinterpretation · Brightness alteration · Color alteration · Dreaming enhancement · Auditory enhancement · Visual morphing · Visual processing suppression · Internal hallucinations · Auditory hallucinations · Environmental orbism / cubism · Visual scenery slicing · External hallucinations
Ganzfeld effect · Auditory distortion · Peripheral vision distortion · Tracers · Visual drifting · Music enhancement · Auditory suppression · Auditory misinterpretation · Brightness alteration · Color alteration · Dreaming enhancement · Auditory enhancement · Visual morphing · Visual processing suppression · Internal hallucinations · Auditory hallucinations · Environmental orbism / cubism · Visual scenery slicing · External hallucinations
Nystagmus (eye wobbles) · Spontaneous body sensations · Body high · Muscle relaxation · Pain suppression · Sedation · Bodily lightness · Nausea · Dry mouth · Laughter fits · Physical fatigue · Pupil dilation · Wakefulness · Salivation · Sexual arousal suppression · Sexual arousal enhancement · Headache · Insomnia · Restlessness · Abnormal heartbeat · Vasoconstriction · Vomiting · Bodily dissociation
Muscle relaxation · Pain suppression · Sedation · Bodily lightness · Nausea · Dry mouth · Laughter fits · Physical fatigue · Pupil dilation · Wakefulness · Salivation · Sexual arousal suppression · Sexual arousal enhancement · Headache · Insomnia · Restlessness · Vasoconstriction · Vomiting · Bodily dissociation
Confusion · Focus suppression · Information processing suppression · Thought disorganization · Pattern recognition suppression · Cognitive euphoria · Thought deceleration · Memory fragmentation · Introspection enhancement · Cognitive fatigue · Language suppression · Suggestibility enhancement · Humor enhancement · Conceptual thinking · Delusions of sobriety · Thought loops · Creativity enhancement · Amnesia · Delirium
Thought disorganization · Pattern recognition suppression · Cognitive euphoria · Thought deceleration · Memory fragmentation · Introspection enhancement · Cognitive fatigue · Language suppression · Humor enhancement · Conceptual thinking · Delusions of sobriety · Thought loops · Creativity enhancement · Amnesia · Delirium
Emotional lability · Dysphoria
Social disconnection · Craving · Sociability suppression · Ego inflation · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Sociability enhancement · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Timeline
First alerts emerge 15–30 minutes after ingestion: a subtle cognitive slowing and mild sense of detachment. Physical effects are minimal at this stage.
Dissociative effects build progressively over 15–30 minutes. Perceptual distortions develop — altered sound processing, spatial warping, and increasing detachment from the body. Heart rate and blood pressure begin to rise.
Maximum dissociation sustained for 1–2 hours. Hallucinations, depersonalization, and anterograde amnesia are most prominent. Motor coordination is severely impaired.
Intensity diminishes but dissociative effects persist at a reduced level for 30–60 minutes. Cognitive function begins to return, though confusion and disorientation may linger. Motor impairment gradually improves.
Effects progressively fade over 30–60 minutes. Residual confusion, difficulty concentrating, and mild perceptual oddities persist. Physical coordination recovers but remains below baseline.
Residual cognitive effects — mild dissociation, fatigue, difficulty concentrating, and mood changes — may persist for 4–24 hours. Sleep quality may be impaired. Memory of the peak experience may be fragmentary or absent.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- ketamine · phencyclidine · methoxetamine
Toxicity
No lethal dose has been established for diphenidine in any species. The exact toxic dose in humans is unknown.safety citation needed
Acute toxicity
In hospitalized cases, 76% had elevated blood pressure, 47% had a racing heart, and 65% had altered mental status.[7] Nearly half were severely intoxicated; half required sedation with benzodiazepines or propofol. Median hospital stay was 2 days.
A separate Italian case showed constricted pupils, raised body temperature, and rapid breathing, though other drugs were also present.[6]
Organ damage
Muscle breakdown and acute kidney injury have been reported in diphenidine intoxications.[9] No bladder damage has been documented — unlike with chronic ketamine use. The ACMD notes this absence may reflect fewer chronic users rather than genuine safety.[9]
Deaths
As of the 2023 ACMD review, 48 deaths involving diphenidine have been identified worldwide, with 37 in the UK (primarily 2014–2016).[9] Only 14 were attributed solely to diphenidine or methoxphenidine; the majority involved multiple substances. A fatal case in Japan mapped tissue distribution post-mortem,[14][18] and three deaths attributed primarily to methoxphenidine also showed diphenidine in post-mortem blood.[19]
Psychological Risks
Acute psychological disturbance is a defining feature of diphenidine intoxication. Clinical presentations include severe agitation, confusion, hallucinations, delusions, paranoia, inability to communicate, and memory blackouts.[7][6][5]
As a potent glutamate blocker, diphenidine can trigger or worsen psychotic episodes in vulnerable individuals. No prospective data on psychiatric outcomes following diphenidine exposure have been published, and no diphenidine-specific data exist on persisting perceptual disturbances.
Tolerance & Dependence
No animal studies or human reports of diphenidine dependence or withdrawal have been documented.[9] One case of withdrawal from the related compound methoxphenidine suggests the class may carry withdrawal potential.[9]
Diphenidine increases dopamine release in reward circuits[8] — a property absent in Methoxphenidine that signals greater abuse liability. Community estimates of a 5-day tolerance half-life and 1.5-week full reset are unconfirmed by any published source.safety citation needed
Drug Interactions
No controlled interaction studies have been published for diphenidine. All data derive from co-exposure in clinical case reports.
Depressant combinations
Combining diphenidine with opioids, benzodiazepines, or alcohol compounds sedation and suppresses breathing. Designer benzodiazepines and alcohol have been co-detected in clinical cases.[6][7]
Stimulant combinations
Diphenidine alone raises blood pressure in 76% of hospitalized cases. Adding stimulants compounds this — blood pressure and heart rate rise together in an additive or synergistic way. Amphetamine, MDMA, methylphenidate, and α-PVP have been co-detected in cases.[7]
Serotonergic combinations
Diphenidine has negligible serotonin activity itself,[1] so serotonin syndrome from the compound alone is unlikely. Combinations with MAOIs, SSRIs, or MDMA have not been formally evaluated; indirect effects through glutamate-serotonin signaling cannot be ruled out.
Metabolic interactions
Diphenidine is processed by multiple liver enzymes.[3] Drugs that inhibit those enzymes could raise diphenidine blood levels and extend its effects. Whether diphenidine alters the metabolism of other drugs is unknown.
Contraindications
7 knownHeart conditions
Pre-existing high blood pressure, irregular heartbeat, or structural heart disease are relative contraindications. Blood pressure elevation occurred in 76% of hospitalized cases and rapid heartbeat in 47%.[7]
Psychiatric vulnerability
Personal or family history of psychotic disorders is a relative contraindication. Diphenidine produces hallucinations, delusions, and paranoia[5] and can trigger or worsen psychotic episodes.[1]
Kidney impairment
Acute kidney injury has been documented in diphenidine intoxications.[9] Pre-existing kidney impairment increases risk and could prolong exposure to active metabolites.
Liver impairment
Diphenidine is extensively processed by the liver.[3] Impaired liver function could reduce clearance and increase the drug's concentration in the body.
Pregnancy
No reproductive toxicity data exist for diphenidine. NMDA signaling is critical for fetal brain development; class-level animal evidence contraindicates NMDA antagonist exposure during pregnancy.safety citation needed
Harm Reduction[edit]
Forms & Identification
No published physical characterization data exist for diphenidine, making visual identification alone unreliable. Reagent testing is essential for distinguishing it from other dissociatives or adulterants. Market products have been found blended with synthetic cannabinoids[11] — test every batch independently.
Without knowing purity, precise dosing is difficult. A milligram-precision scale and conservative initial doses are baseline precautions.
Guidelines
- Start with the lowest effective dose and wait at least 90 minutes before considering redosing — onset can be slow and unpredictable
- Use a milligram-precision scale; estimating doses of an active powder is dangerous
- Have a sober sitter present who understands dissociative states
- Avoid combining with other substances, particularly depressants and stimulants
- Stay hydrated but avoid alcohol
- Remove hazards from the environment — sharp objects, stairs, open water
- Avoid driving or operating machinery for at least 8 hours following use
- If smoking or vaporizing, be aware that onset is near-instantaneous and far more disorienting than oral use
Set & Setting
Diphenidine's prominent amnestic effects and potential for severe agitation make environment particularly important. A calm, familiar space with minimal stimulation reduces the likelihood of panic or confusion.
A sober, trusted sitter is strongly recommended. Memory blackouts and inability to communicate are documented in clinical cases[6] — the user may be unable to recognize danger or request help.
Aftercare & integration. The prominent amnesia associated with diphenidine means post-experience processing may be fragmentary. Allow at least 24 hours of rest before returning to demanding activities. Sleep, food, and water support physical recovery.
Because memory is often incomplete, a sitter's account of what happened can fill important gaps. Seek professional support if residual confusion, anxiety, or perceptual disturbance persists beyond 48 hours.
Recovery & Support
No published cases of diphenidine dependence exist, but its dopamine-releasing properties provide a mechanistic basis for habit formation.[8] If use becomes compulsive or difficult to stop, the same resources that support dissociative and stimulant misuse apply: professional addiction counseling, peer support, and harm reduction services.
Escalating frequency, using alone, and difficulty controlling dose are early warning signs — regardless of whether formal dependence criteria are met.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Unresponsiveness, seizure, chest pain, extremely high body temperature, or complete inability to communicate beyond what is expected from dissociation. Severe agitation where the person is a danger to themselves or others. Blue or grey skin coloring.
Immediate steps:
- Call emergency services immediately if the person is unconscious, seizing, or showing signs of cardiovascular distress
- Place an unconscious but breathing person in the recovery position
- Do not restrain an agitated person unless there is immediate danger of self-harm — restraint can worsen agitation and raise body temperature
- Keep the environment quiet and low-stimulation
- Monitor breathing and pulse while waiting for help
What to tell the dispatcher: Name the substance (diphenidine, a dissociative), approximate amount taken if known, time of ingestion, current symptoms, and any other substances consumed. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies.
Legal Status[edit]
Diphenidine is controlled internationally under Schedule II of the Convention on Psychotropic Substances 1971, adopted in April 2021 on the recommendation of the WHO Expert Committee.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule II (Convention on Psychotropic Substances 1971) | 64th CND, April 2021; implementing 43rd ECDD recommendation[5] |
| United States | Not scheduled (CSA) | Subject to international Schedule II obligations; Federal Analogue Act may apply if intended for human consumption. No domestic scheduling rule confirmed as of May 2026 |
| United Kingdom | Psychoactive Substances Act 2016 (blanket ban); Class B MDA 1971 recommended | ACMD recommended Class B, Schedule 1 under Misuse of Drugs Act 1971 on 26 May 2023;[9] legislative implementation status pending at time of writing |
| Canada | Schedule I (CDSA) | Listed as DEP, classified as analogue of MT-45; effective November 2016[12] |
| Germany | Controlled substance | Production and sale illegal; possession for personal use not penalizedcitation needed |
| Australia | Controlled substance | Listed on Office of Drug Control controlled substances registercitation needed |
| Sweden | Controlled under NPS legislation | Monitored through the STRIDA clinical-toxicological surveillance project[7] |
Legal status changes frequently and varies by jurisdiction. This information reflects available records as of May 2026 and is not legal advice. Verify current laws in any relevant jurisdiction before relying on this information.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- ketamine · phencyclidine · methoxetamine
Toxicity
No lethal dose has been established for diphenidine in any species. The exact toxic dose in humans is unknown.safety citation needed
Acute toxicity
The best-characterized data come from the Swedish STRIDA case series (14 confirmed cases).[8] Blood pressure elevation occurred in 76% of hospitalized cases, racing heart in 47%, and altered mental status in 65%. Nearly half were classified as severely intoxicated, and sedation with benzodiazepines or propofol was required in 50% of cases. Median hospitalization was 2 days.
A separate Italian case documented constricted pupils (atypical for NMDA dissociatives), increased body temperature, and rapid breathing, though co-ingestion of methylphenidate and diclazepam confounded that presentation.[7]
Organ damage
Muscle breakdown and acute kidney injury have been reported in diphenidine intoxications.[10] No bladder damage has been documented — an important distinction from chronic ketamine use, which produces well-characterized urological harm. The ACMD notes this absence may reflect fewer chronic users and shorter follow-up rather than genuine safety.[10]
Deaths
As of the 2023 ACMD review, 48 deaths involving diphenidine have been identified worldwide, with 37 in the UK (primarily 2014–2016). Only 14 were attributed solely to diphenidine or methoxphenidine; the majority involved multiple substances.[10]
A fatal case in Japan involved diphenidine alongside synthetic cannabinoids; tissue distribution was mapped post-mortem.[14][18] Three deaths attributed primarily to methoxphenidine also showed diphenidine in post-mortem blood, though it was unclear whether diphenidine arose from methoxphenidine metabolism or separate intake.[19]
Psychological Risks
Acute psychological disturbance is a defining feature of diphenidine intoxication. Clinical presentations include severe agitation, confusion, hallucinations, delusions, paranoia, inability to communicate, and memory blackouts.[8][7][6]
As a potent NMDA antagonist, diphenidine carries risk of triggering or worsening psychotic episodes in vulnerable individuals. No prospective data on psychiatric outcomes following diphenidine exposure have been published. The prevalence of HPPD following dissociative use is poorly characterized, and no diphenidine-specific data exist.
Tolerance & Dependence
No animal studies or human reports of dependence or withdrawal have been documented specifically for diphenidine.[10] One case of methoxphenidine withdrawal after abrupt cessation has been reported, suggesting the diarylethylamine class may carry withdrawal potential.[10]
Diphenidine's dopamine release in reward circuits[9] provides the strongest available signal for addictive potential — a functional property absent in the structurally related methoxphenidine. No substance-specific tolerance data exist. Community estimates of a 5-day tolerance half-life and 1.5-week full reset are unconfirmed by any published source.safety citation needed
Drug Interactions
No controlled interaction studies have been published for diphenidine. All data derive from co-exposure in clinical case reports.
Depressant combinations
Combining diphenidine with opioids, benzodiazepines, or alcohol is expected to compound sedation and respiratory depression. Designer benzodiazepines and alcohol have been co-detected in clinical cases.[7][8]
Stimulant combinations
Given that 76% of hospitalized diphenidine cases showed elevated blood pressure, adding stimulants carries compounded cardiovascular risk — additive or synergistic increases in blood pressure and heart rate. Amphetamine, MDMA, methylphenidate, and α-PVP were co-detected in multiple STRIDA cases.[8]
Serotonergic combinations
Diphenidine itself has negligible serotonin reuptake activity,[1] making serotonin syndrome from the compound alone unlikely. However, combinations with serotonergic substances (MAOIs, SSRIs, MDMA) have not been formally evaluated, and indirect effects through glutamate-serotonin crosstalk cannot be excluded.
Contraindications
7 knownHeart conditions
Pre-existing high blood pressure, irregular heartbeat, or structural heart disease are relative contraindications given the 76% rate of blood pressure elevation and 47% rate of rapid heartbeat observed in hospitalized cases.[8]
Psychiatric vulnerability
Personal or family history of psychotic disorders represents a relative contraindication. Diphenidine produces hallucinations, delusions, and paranoia[6] and disrupts sensory gating,[1] with potential to trigger or worsen psychotic episodes.
Kidney impairment
Given documented cases of muscle breakdown and acute kidney injury,[10] pre-existing kidney impairment increases risk. Reduced kidney function could prolong exposure to active metabolites.
Harm Reduction[edit]
Forms & Identification
No published physical characterization data (melting point, solubility) exist for diphenidine, making visual identification alone unreliable. Reagent testing is essential for distinguishing it from other dissociatives or adulterants.
Market products have been found blended with synthetic cannabinoids in Japan,[12] underscoring the importance of testing each batch independently. Without knowing purity, precise dosing is difficult — a milligram-precision scale and conservative initial doses are baseline precautions.
Guidelines
- Start with the lowest effective dose and wait at least 90 minutes before considering redosing — onset can be slow and unpredictable
- Use a milligram-precision scale; estimating doses of an active powder is dangerous
- Have a sober sitter present who understands dissociative states
- Avoid combining with other substances, particularly depressants and stimulants
- Stay hydrated but avoid alcohol
- Remove hazards from the environment — sharp objects, stairs, open water
- Avoid driving or operating machinery for at least 8 hours following use
- If smoking or vaporizing, be aware that onset is near-instantaneous and far more disorienting than oral use
Set & Setting
Diphenidine's prominent amnestic effects and potential for severe agitation make environment particularly important. A calm, familiar space with minimal stimulation reduces the likelihood of panic or confusion during the dissociative state.
A sober, trusted sitter is strongly recommended. The inability to communicate and memory blackouts documented in clinical cases[7] mean the user may be unable to recognize danger or ask for help.
Aftercare & integration. The prominent amnesia associated with diphenidine means post-experience processing may be fragmentary. Allow at least 24 hours of rest before returning to demanding activities. Sleep, gentle food, and water support physical recovery.
Because memory of the experience is often incomplete, a sitter's account of what happened can fill important gaps. If residual confusion, anxiety, or perceptual disturbance persists beyond 48 hours, seek professional support.
Recovery & Support
No published cases of diphenidine-specific dependence exist, but the compound's dopamine-releasing properties provide a mechanistic basis for habit formation.[9] If use becomes compulsive or difficult to stop, the same resources that support dissociative and stimulant misuse apply: professional addiction counseling, peer support groups, and harm reduction services.
Escalating frequency of use, using alone, and difficulty controlling dose are early warning signs regardless of whether formal dependence criteria are met.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Unresponsiveness, seizure, chest pain, extremely high body temperature, or complete inability to communicate beyond what is expected from dissociation. Severe agitation where the person is a danger to themselves or others. Blue or grey skin coloring.
Immediate steps:
- Call emergency services immediately if the person is unconscious, seizing, or showing signs of cardiovascular distress
- Place an unconscious but breathing person in the recovery position
- Do not restrain an agitated person unless there is immediate danger of self-harm — restraint can worsen agitation and raise body temperature
- Keep the environment quiet and low-stimulation
- Monitor breathing and pulse while waiting for help
What to tell the dispatcher: Name the substance (diphenidine, a dissociative), approximate amount taken if known, time of ingestion, current symptoms, and any other substances consumed. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies.
Legal Status[edit]
Diphenidine is controlled at the international level under Schedule II of the Convention on Psychotropic Substances 1971, following the recommendation of the WHO Expert Committee on Drug Dependence at its 43rd meeting in October 2020.[6] The 64th session of the Commission on Narcotic Drugs adopted this recommendation in April 2021. National-level controls vary: diphenidine is specifically scheduled in Canada and Australia, covered by blanket psychoactive substance legislation in the UK, and not formally scheduled under the US Controlled Substances Act as of May 2026.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule II (Convention on Psychotropic Substances 1971) | 64th CND, April 2021; implementing 43rd ECDD recommendation[6] |
| United States | Not scheduled (CSA) | Subject to international Schedule II obligations; Federal Analogue Act may apply if intended for human consumption. No domestic scheduling rule confirmed as of May 2026 |
| United Kingdom | Psychoactive Substances Act 2016 (blanket ban); Class B MDA 1971 recommended | ACMD recommended Class B, Schedule 1 under Misuse of Drugs Act 1971 on 26 May 2023;[10] legislative implementation status pending at time of writing |
| Canada | Schedule I (CDSA) | Listed as DEP, classified as analogue of MT-45; effective November 2016[13] |
| Germany | Controlled substance | Production and sale illegal; possession for personal use not penalizedcitation needed |
| Australia | Controlled substance | Listed on Office of Drug Control controlled substances registercitation needed |
| Sweden | Controlled under NPS legislation | Monitored through the STRIDA clinical-toxicological surveillance project[8] |
Canada's classification of diphenidine as an MT-45 structural analog under Schedule I is notable, as it groups diphenidine with an opioid-active compound on the basis of structural similarity rather than shared pharmacological mechanism.
Frequently asked questions
What is Diphenidine?
Diphenidine is a synthetic dissociative of the diarylethylamine class, first synthesized in 1924 and sold on research-chemical markets since 2013. It acts as an uncompetitive NMDA receptor antagonist with secondary dopamine reuptake inhibition and was internationally scheduled in 2021.
How long does Diphenidine last?
Total duration by route of administration — Oral: 2 – 5 hours; Rectal: 5 – 7 hours; Smoked: 1 – 3 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Diphenidine?
Psychedex publishes a dosage table for Diphenidine on this page covering these routes of administration: oral, rectal, smoked. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Diphenidine?
The highest-severity documented interactions for Diphenidine: GHB, GBL (Lethal), Ibogaine (Lethal), Amphetamines (Dangerous), Anticholinergics (Dangerous), Antihistamines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Diphenidine addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Diphenidine: tolerance builds moderate; full reset takes 10 days; cross-tolerance develops with ketamine, phencyclidine, methoxetamine, methoxphenidine, dextromethorphan. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4] ^abcdWallach J, Brandt SD (2018) 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_148
- [5]
- [6]
references
- [1]
- [2]
- [3]
- [4] ^abcdWallach J, Brandt SD (2018) 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_148
- [5] ^abcWallach J, Kavanagh PV, McLaughlin G, Morris N, Power JD, Elliott SP, Mercier MS, Lodge D, Morris H, Dempster NM, Brandt SD (2015) Preparation and characterization of the 'research chemical' diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers — Drug Testing and Analysis doi:10.1002/dta.1689
- [6]